Corinna Trebst
Overview
Explore the profile of Corinna Trebst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
3828
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hecker M, Fitzner B, Ludwig-Portugall I, Bohne F, Heyland E, Klehmet J, et al.
Front Immunol
. 2025 Feb;
16:1531447.
PMID: 39949773
Background: High-dose glucocorticoids are the standard treatment for acute relapses in patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). Therapeutic apheresis can be considered for the escalation...
2.
Haussler V, Trebst C, Engels D, Pellkofer H, Havla J, Duchow A, et al.
J Neurol Neurosurg Psychiatry
. 2024 Dec;
PMID: 39730197
Background: Recurrent attacks in neuromyelitis optica spectrum disorders (NMOSDs) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can lead to severe disability. We aimed to analyse the real-world use of immunotherapies...
3.
Nicolescu M, Haussler V, Paul F, Oertel F, Schindler P, Strobl J, et al.
J Neurol
. 2024 Dec;
272(1):86.
PMID: 39708205
Objective: In this multicentric study, we were interested in the vision-related quality of life and its association with visual impairment in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein...
4.
Schwake C, Ladopoulos T, Haussler V, Kleiter I, Ringelstein M, Aktas O, et al.
J Neurol Neurosurg Psychiatry
. 2024 Nov;
PMID: 39496464
Background: Incomplete attack remission is the main cause of disability in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Apheresis therapies such as plasma exchange and immunoadsorption are widely used in neuroimmunology....
5.
Ringelstein M, Asseyer S, Lindenblatt G, Fischer K, Pul R, Skuljec J, et al.
Neurology
. 2024 Oct;
103(9):e209888.
PMID: 39353149
Background And Objectives: Attack prevention is crucial in managing neuromyelitis optica spectrum disorders (NMOSDs). Eculizumab (ECU), an inhibitor of the terminal complement cascade, was highly effective in preventing attacks in...
6.
Passoke S, Stern C, Haussler V, Kumpfel T, Havla J, Engels D, et al.
J Neurol Neurosurg Psychiatry
. 2024 Jul;
PMID: 39084862
Background: Data on cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are limited to studies with small sample sizes. Therefore, we aimed to analyse the extent, characteristics and...
7.
Schneider-Hohendorf T, Wunsch C, Falk S, Raposo C, Rubelt F, Mirebrahim H, et al.
Brain
. 2024 Jul;
148(3):933-940.
PMID: 39021292
Epstein-Barr virus (EBV) infection has long been associated with the development of multiple sclerosis (MS). Patients with MS have elevated titres of EBV-specific antibodies in serum and show signs of...
8.
Fricke L, Kruger K, Trebst C, Brutt A, Dilger E, Eichstadt K, et al.
Mult Scler J Exp Transl Clin
. 2024 Jun;
10(2):20552173241260151.
PMID: 38910839
Background: Previous investigations of multiple sclerosis (MS)-related healthcare have focused on utilisation of specific individual health services (e.g. hospital care, office-based neurologists) by people with MS (PwMS). Meanwhile, little is...
9.
Kumpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Haussler V, et al.
J Neurol
. 2024 Apr;
271(6):3702-3707.
PMID: 38578500
No abstract available.
10.
Jendretzky K, Bajor A, Lezius L, Hummert M, Konen F, Grosse G, et al.
Sci Rep
. 2024 Mar;
14(1):7293.
PMID: 38538701
Optic neuritis is often an initial symptom in multiple sclerosis (MS) or clinically isolated syndrome (CIS), yet comprehensive studies using the 2017 McDonald criteria for MS are scarce. Patient records...